Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABY 035

Drug Profile

ABY 035

Alternative Names: ABY-035/AFO2; ABY035; AFB-035

Latest Information Update: 27 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affibody
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis
  • Phase I/II Psoriasis

Most Recent Events

  • 20 Jan 2020 Phase-II clinical trials in Psoriatic arthritis (Treatment-resistant) in Hungary (SC) (EudraCT2019-003405-94)
  • 01 Dec 2019 Phase-I clinical trials in Plaque psoriasis in USA (unspecified route) (NCT03580278)
  • 20 Feb 2019 Affibody completes enrolment in the phase II AFFIRM-35 trial for Plaque psoriasis in Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top